Seres Therapeutics, Inc. – NASDAQ:MCRB

Add to watchlist

$16.25

+15.36

+1732.43%

Market open

Closed in about 6 hours

-17.10%

month

-17.10%

quarter

-37.09%

year

Market Cap	158.90M
Enterprise value	631.81M

P/E	-2.61
EV/Sales	88.63
EV/EBITDA	-2.66
Price/Sales	88.69
Price/Book	58.63
PEG ratio	0.01
EPS	-0.60

Revenue	N/A
EBITDA	-69.67M
Income	-82.68M
Revenue Q/Q	N/A
Revenue Y/Y	2380.87%

Profit margin	-3509.5%
Oper. margin	-3458.05%
Gross margin	0%
EBIT margin	-3458.05%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Seres Therapeutics, Inc. (NASDAQ:MCRB): Profit margin
Jun 2023	126.47M	46.55M	36.81%
Sep 2023	310K	-47.85M	-15436.77%
Dec 2023	64K	-41.24M	-64450%
Mar 2024	0	-40.13M

Seres Therapeutics Financials Estimate

Q Y

Seres Therapeutics, Inc. (NASDAQ:MCRB): Analyst Estimates
Mar 2024	0	-40.13M
Sep 2025	94.96K	-34.90M	-36751.24%
Oct 2025	0	-30.68M
Dec 2025	0	-31.16M

Analysts Price target
Financials & Ratios estimates

Seres Therapeutics, Inc. (NASDAQ:MCRB): Debt to assets
Jun 2023	406387000	383.77M	94.44%
Sep 2023	367699000	382.82M	104.11%
Dec 2023	358600000	403.45M	112.51%
Mar 2024	341262000	401M	117.51%

Seres Therapeutics, Inc. (NASDAQ:MCRB): Cash Flow
Jun 2023	65.98M	10.51M	58.17M
Sep 2023	-59.25M	-1.79M	1.44M
Dec 2023	-47.49M	-877K	6.42M
Mar 2024	-35.23M	-62K	18.76M

Seres Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Seres Therapeutics, Inc. (NASDAQ:MCRB): Employee count
Aug 2023	431
Sep 2023	431
Oct 2023	431
Nov 2023	431
Dec 2023	431
Jan 2024	431
Feb 2024	431
Mar 2024	233
Apr 2024	233
May 2024	233
Jun 2024	233
Jul 2024	233

Seres Therapeutics
Hedge Funds Holdings Q1 2023

44.78% -40.97%

of MCRB is owned by hedge funds

82 -41

hedge funds hold MCRB stock

48.40M -56.67M

shares is hold by hedge funds

MCRB hedge funds holdings changes

Seres Therapeutics
Insider Trading

Seres Therapeutics, Inc. (NASDAQ:MCRB): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	0	36381
May 2024	0	6901
Aug 2024	0	31623
Oct 2024	0	24308
Nov 2024	0	6022

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	18 Nov 2024	DESROSIER THOMAS officer: Chief Le..	Common Stock	878	$0.54	$475
Sale	18 Nov 2024	VON MOLTKE LISA officer: See Remarks officer: See Remarks	Common Stock	977	$0.54	$529
Sale	18 Nov 2024	SHAFF ERIC D. director, officer: CEO and President director, officer: CEO and Pres..	Common Stock	2,505	$0.54	$1,355
Sale	18 Nov 2024	YOUNG TERESA L. officer: See Remarks officer: See Remarks	Common Stock	735	$0.54	$398
Sale	18 Nov 2024	HENN MATTHEW R. officer: See Remarks officer: See Remarks	Common Stock	927	$0.54	$502
Option	15 Nov 2024	DESROSIER THOMAS officer: Chief Le..	Common Stock	2,656	N/A	N/A
Option	15 Nov 2024	DESROSIER THOMAS officer: Chief Le..	Restricted Stock Units	2,656	N/A	N/A
Option	15 Nov 2024	VON MOLTKE LISA officer: See Remarks officer: See Remarks	Common Stock	2,969	N/A	N/A
Option	15 Nov 2024	VON MOLTKE LISA officer: See Remarks officer: See Remarks	Restricted Stock Units	2,969	N/A	N/A
Option	15 Nov 2024	SHAFF ERIC D. director, officer: CEO and President director, officer: CEO and Pres..	Common Stock	7,812	N/A	N/A

MCRB insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application COMPOSITIONS AND METHODS FOR INHIBITION OF PATHOGENIC BACTERIAL GROWTH Filling date: 23 Nov 2021 Issue date: 11 Aug 2022	23 Nov 2021	11 Aug 2022
Grant	Grant Utility: Synergistic bacterial compositions and methods of production and use thereof Filling date: 21 Dec 2018 Issue date: 8 Mar 2022	21 Dec 2018	8 Mar 2022
Application	Application COMPOSITIONS FOR STABILIZING BACTERIA AND USES THEREOF Filling date: 5 Dec 2019 Issue date: 20 Jan 2022	5 Dec 2019	20 Jan 2022
Grant	Grant Utility: Compositions and methods for inhibition of pathogenic bacterial growth Filling date: 4 Feb 2014 Issue date: 30 Nov 2021	4 Feb 2014	30 Nov 2021
Application	Application TREATMENT OF A CANCER BY MICROBIOME MODULATION Filling date: 28 Mar 2019 Issue date: 25 Nov 2021	28 Mar 2019	25 Nov 2021
Application	Application COMPOSITIONS AND METHODS Filling date: 12 Apr 2021 Issue date: 30 Sep 2021	12 Apr 2021	30 Sep 2021
Application	Application NETWORK-BASED MICROBIAL COMPOSITIONS AND METHODS Filling date: 4 Jan 2021 Issue date: 19 Aug 2021	4 Jan 2021	19 Aug 2021
Application	Application COMPOSITIONS AND METHODS Filling date: 5 Apr 2021 Issue date: 12 Aug 2021	5 Apr 2021	12 Aug 2021
Application	Application DESIGNED BACTERIAL COMPOSITIONS AND USES THEREOF Filling date: 24 May 2019 Issue date: 1 Jul 2021	24 May 2019	1 Jul 2021
Application	Application Synergistic Bacterial Compositions and Methods of Production and Use Thereof Filling date: 14 Dec 2020 Issue date: 10 Jun 2021	14 Dec 2020	10 Jun 2021

Seres Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 5 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 4 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 8 Aug 2023	Q2 2023 Earnings Call Transcript

MCRB earnings call transcripts

Seres Therapeutics
Executives

Insider	Age	Compensation
Mr. Eric D. Shaff M.B.A. (1976) Pres, Chief Executive Officer & Director	49	$1,090,000
Mr. Thomas J. DesRosier (1955) Chief Legal Officer, Executive Vice President & Sec.	70	$719,550
Dr. David S. Ege Ph.D. (1974) Executive Vice President & Chief Technology Officer	51	$142,710

Seres Therapeutics
Latest News

Monday, 16 December 2024
07:00	Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference	globenewswire.com
Friday, 22 November 2024
07:00	Seres Therapeutics to Participate in Piper Sandler Healthcare Conference	globenewswire.com
Wednesday, 13 November 2024
10:28	Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript	seekingalpha.com
Wednesday, 6 November 2024
07:00	Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024	globenewswire.com
Monday, 30 September 2024
17:15	Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A	globenewswire.com
Friday, 27 September 2024
15:26	Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé	businesswire.com
Thursday, 26 September 2024
16:01	Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30	globenewswire.com
Monday, 23 September 2024
00:14	Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade	seekingalpha.com
Friday, 13 September 2024
07:00	Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference	globenewswire.com
Thursday, 12 September 2024
07:00	Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)	globenewswire.com
Wednesday, 4 September 2024
10:37	After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)	zacks.com
Thursday, 15 August 2024
10:56	Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now	zacks.com
Tuesday, 13 August 2024
15:35	Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript	seekingalpha.com
Tuesday, 6 August 2024
07:00	Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science	globenewswire.com
07:00	Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024	globenewswire.com
Friday, 7 June 2024
16:00	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 6 June 2024
07:00	Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023	prnewswire.com
06:30	Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science	globenewswire.com
Saturday, 11 May 2024
17:34	Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript	Seeking Alpha
Monday, 6 May 2024
09:30	Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024	Business Wire
Tuesday, 5 March 2024
15:33	Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript	Seeking Alpha
10:18	Gold Price Alert: Gold Spot Prices Just Hit a Record High Today	InvestorPlace
Tuesday, 28 November 2023
09:18	Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET	Business Wire
Saturday, 4 November 2023
11:52	Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript	Seeking Alpha
Monday, 30 October 2023
17:30	Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST	Business Wire
Friday, 1 September 2023
14:03	Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy	Seeking Alpha
Tuesday, 8 August 2023
09:55	Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates	Zacks Investment Research
Wednesday, 7 June 2023
11:16	Best Penny Stocks To Buy? 5 With Big News This Week	PennyStocks
Friday, 2 June 2023
07:00	Seres Therapeutics to Present at Jefferies Healthcare Conference	Business Wire
Tuesday, 9 May 2023
09:57	Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 29 Jul 2025

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough
Seeking Alpha 27 Nov 2023

SunPower: Not Yet Done
Seeking Alpha 1 Sep 2023

Seres Therapeutics: Approved Drug And Nestle Partnership Make It A Buy
Seeking Alpha 3 Aug 2023

Seres Therapeutics: VOWST's Time To Shine
Seeking Alpha 23 May 2023

Seres Q1 Earnings: Major News For Investors
Seeking Alpha 3 May 2023

Seres Gets FDA Approval And The Share Price Goes Down!
Seeking Alpha 5 Apr 2023

Seres Therapeutics: Binary Catalyst Unlocking
Seeking Alpha 8 Feb 2023

Sana Biotechnology: Time And Cash Burn Are The Enemies
Seeking Alpha 6 Feb 2023

Seres Therapeutics: FDA Approval Straight Ahead
Seeking Alpha 5 Feb 2023

The Clock Is Ticking For Seres Therapeutics: I'm Not Afraid

Frequently Asked Questions (FAQ)

What's the price of Seres Therapeutics stock today?

One share of Seres Therapeutics stock can currently be purchased for approximately $16.25.
When is Seres Therapeutics's next earnings date?

Unfortunately, Seres Therapeutics's (MCRB) next earnings date is currently unknown.
Does Seres Therapeutics pay dividends?

No, Seres Therapeutics does not pay dividends.
How much money does Seres Therapeutics make?

Seres Therapeutics has a market capitalization of 158.90M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1672.24% to 126.33M US dollars.
What is Seres Therapeutics's stock symbol?

Seres Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "MCRB".
What is Seres Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Seres Therapeutics?

Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Seres Therapeutics's key executives?
Seres Therapeutics's management team includes the following people:
- Mr. Eric D. Shaff M.B.A. Pres, Chief Executive Officer & Director(age: 49, pay: $1,090,000)
- Mr. Thomas J. DesRosier Chief Legal Officer, Executive Vice President & Sec.(age: 70, pay: $719,550)
- Dr. David S. Ege Ph.D. Executive Vice President & Chief Technology Officer(age: 51, pay: $142,710)
How many employees does Seres Therapeutics have?

As Jul 2024, Seres Therapeutics employs 233 workers.
When Seres Therapeutics went public?

Seres Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 26 Jun 2015.
What is Seres Therapeutics's official website?

The official website for Seres Therapeutics is serestherapeutics.com.
Where are Seres Therapeutics's headquarters?

Seres Therapeutics is headquartered at 200 Sidney Street, Cambridge, MA.
How can i contact Seres Therapeutics?

Seres Therapeutics's mailing address is 200 Sidney Street, Cambridge, MA and company can be reached via phone at +61 79459626.

Seres Therapeutics, Inc.

serestherapeutics.com

Exchange:

NASDAQ

Full time employees:

233

Industry:

Biotechnology

Sector:

Healthcare

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

+61 79459626

200 Sidney Street
Cambridge, MA 02139

CIK: 0001609809
ISIN: US81750R1023
CUSIP: 81750R102